Ongoing Clinical Trials for Ventricular Extrasystoles
There are currently 2 ongoing clinical trials investigating treatments for ventricular extrasystoles. These studies are taking place in Spain and France, and are testing various medications to reduce irregular heartbeats and prevent potential complications. The trials compare different treatment approaches, including beta-blockers and antiarrhythmic drugs, to help determine which medications are most effective for managing this heart rhythm condition.
Clinical trial locations
- France
- Spain
Comparison of Carvedilol and Flecainide Treatment in Patients with Idiopathic Ventricular Arrhythmias
This trial is comparing two different medications for treating irregular heartbeats that come from the lower chambers of the heart when no underlying cause can be identified. The study aims to find out which medication works better at reducing these irregular rhythms.
Who can participate:
You may be eligible if you are at least 18 years old and have idiopathic ventricular arrhythmias, which means irregular heart rhythms originating from the lower chambers of the heart without a known cause. You must be able to undergo 24-hour heart monitoring using a portable recording device and provide informed consent. Both males and females can participate.
Who cannot participate:
You cannot join this study if you are under 18 or over 65 years old, pregnant, or breastfeeding. The trial excludes people with structural heart disease, previous heart attacks or heart surgery, other types of heart rhythm disorders, or those currently taking other antiarrhythmic medications. You also cannot participate if you have severe kidney or liver problems, uncontrolled thyroid disorders, known allergies to the study medications, or have participated in other clinical trials within the past 30 days. People with a history of drug or alcohol abuse within the past year or mental conditions affecting their ability to provide informed consent are also excluded.
What the trial involves:
The study compares carvedilol and flecainide, both given as oral tablets. Participants will receive either carvedilol at doses up to 50 mg daily or flecainide at doses up to 300 mg daily for 12 months. Throughout the study, your heart activity will be monitored using a Holter-ECG device, which records your heart rhythms continuously for 24 hours. These recordings will be taken before treatment begins and after completion. The study also evaluates how the medications affect your quality of life and heart function using echocardiography, a test that uses sound waves to create images of your heart. Any side effects will be tracked during the treatment period.
Medications being tested:
Carvedilol is a beta-blocker that works by blocking certain natural chemicals in your body, such as epinephrine, that affect the heart and blood vessels. This helps reduce heart rate, blood pressure, and strain on the heart. Flecainide is an antiarrhythmic medication that stabilizes the electrical activity in the heart by slowing down electrical signals in the heart tissue. Both medications are being studied for their effectiveness in controlling irregular heartbeats originating from the ventricles.
Study of drug combination therapy in asymptomatic patients with frequent premature ventricular contractions and normal heart function to prevent left ventricular dysfunction
This study focuses on people who have frequent extra heartbeats coming from the lower chambers of the heart but don’t experience any symptoms and have normal heart function. The goal is to determine whether treating these patients with medication can prevent future heart problems better than simply monitoring them without treatment.
Who can participate:
You may be eligible if you are between 18 and 85 years old and have frequent premature ventricular contractions occurring in at least 10% of all your heartbeats. You must have no symptoms related to these irregular heartbeats and maintain normal heart pumping function, with a left ventricular ejection fraction of 55% or higher. You can participate even if you have an underlying heart condition, as long as your heart function remains normal. Both males and females are welcome, and you must be able to understand and sign an informed consent form.
Who cannot participate:
You cannot join if you are under 18 or over 75 years old, experience any symptoms related to heart rhythm disturbances such as palpitations, dizziness, or fainting, or have a lower than normal left ventricular ejection fraction. The trial excludes people who have previously been treated with antiarrhythmic drugs or ablation procedures, those who are pregnant or planning to become pregnant, and anyone with less than 10% premature ventricular contractions. You also cannot participate if you have other significant heart conditions, severe kidney or liver disease, known allergies to study medications, a history of substance abuse, or mental conditions that could affect your ability to follow study requirements.
What the trial involves:
The study lasts for 24 months and tests several medications including verapamil, nebivolol, amiodarone, propafenone, bisoprolol, diltiazem, flecainide, and sotalol. You will be assigned to either receive medication treatment or no treatment with regular monitoring only. If you receive medication and it doesn’t reduce your extra heartbeats enough after trying two different drugs, you may be offered a procedure called ablation, which uses heat to destroy small areas of heart tissue causing the irregular rhythms. Throughout the study, doctors will monitor your heart function using cardiac magnetic resonance imaging or heart ultrasound, track changes in your heart’s pumping ability, measure your exercise capacity, and monitor for any side effects. You will have check-ups at 6, 12, 18, and 24 months, and complete quality of life questionnaires.
Medications being tested:
The trial uses antiarrhythmic drugs, which are medications designed to control and reduce premature ventricular contractions and help maintain normal heart rhythm. If medications alone don’t sufficiently reduce the irregular heartbeats, catheter ablation may be used as a secondary treatment option. This is a procedure where small areas of heart tissue causing the irregular beats are destroyed using heat energy delivered through special catheters.
Summary
The two ongoing clinical trials for ventricular extrasystoles are taking place in Spain and France, each investigating different approaches to managing this heart rhythm condition. The Spanish trial focuses specifically on comparing two medications, carvedilol and flecainide, to determine which is more effective for patients with idiopathic ventricular arrhythmias. The French study takes a broader approach by testing multiple medications and investigating whether treating asymptomatic patients with frequent premature ventricular contractions can prevent future heart problems.
Both trials share a common goal of finding better ways to manage irregular heartbeats originating from the heart’s lower chambers. The studies differ in their patient populations, with the Spanish trial focusing on patients with idiopathic arrhythmias regardless of symptom status, while the French trial specifically targets asymptomatic patients with normal heart function. The French study also stands out by including catheter ablation as a potential treatment option if medications prove insufficient.
These trials reflect the ongoing effort to optimize treatment strategies for ventricular extrasystoles and to determine which patients benefit most from medical intervention versus simple monitoring. The research may help doctors make more informed decisions about when to treat and which medications to choose for individual patients.
